Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2007-12-25
2007-12-25
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C530S351000
Reexamination Certificate
active
10823964
ABSTRACT:
Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.
REFERENCES:
patent: 6274552 (2001-08-01), Tamarkin et al.
patent: 6602498 (2003-08-01), Shen
patent: 6753165 (2004-06-01), Cox et al.
patent: 2003/0171284 (2003-09-01), Cox et al.
patent: 2003/0191056 (2003-10-01), Walker et al.
patent: 2003/0195154 (2003-10-01), Walker et al.
patent: 2003/0232032 (2003-12-01), Janson et al.
patent: 2004/0062746 (2004-04-01), Martinez et al.
patent: 2004/0136992 (2004-07-01), Burton et al.
patent: 0692536 (1996-01-01), None
patent: 0712931 (1996-05-01), None
patent: 0767178 (1997-04-01), None
patent: 0816499 (1998-01-01), None
patent: 0819757 (1998-01-01), None
patent: 0821005 (1998-01-01), None
patent: 0845530 (1998-06-01), None
patent: 0845530 (1998-06-01), None
patent: 0859052 (1998-08-01), None
patent: 110969 (2001-06-01), None
patent: 0974600 (2001-09-01), None
patent: WO99/03887 (1999-01-01), None
patent: WO 99/45026 (1999-09-01), None
patent: WO 9945026 (1999-09-01), None
patent: WO00/42175 (2000-07-01), None
patent: WO01/03737 (2001-01-01), None
patent: WO01/62827 (2001-08-01), None
patent: WO01/87925 (2001-11-01), None
patent: WO02/077218 (2002-10-01), None
Pettit et al., J Biol Chem. 1997;272(4):2312-2318.
Kirkpatrick et al., Protein Expr Purif. Feb. 2003;27(2):279-92.
Fu et al., Acta Biochimica et Biophysica Sinica. 2001; 33(4):368-372.
Kim et al., J Biol Chem. Mar. 29, 2002; 277(13):10998-11003.
Katre et al., PNAS USA. 1987;84:1487-1491.
Benjamin et al., Ann Rev Immune. 1984;2:67-101.
Pomroy, et al., “Solubilization of Hydrophobic Peptides by Reversible Cysteine PEGylation,”Biochemical and Biophysical Research Communications, 245: 618-621 (1998).
Albrecht, et al., “Production of Soluble ScFVS with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand,”Bioconjugate Chem., 15: 16-26 (2004).
Sato, et al., “Transglutaminase-Mediated Dual and Site-Specific Incorporation of Poly(ethyleneglycol) Derivatives into a Chimeric Interleukin-2,”Bioconjugate Chem., 11: 502-509 (2000).
Manjula, et al, “Site-Specific PEGylation of Hemogobin at Cys-93(β): Correlation between the Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain,”Bioconjugate Chem., 14: 464-472 (2003).
Pettit, et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling,”The Journal of Biological Chemistry, 272 (4): 2312-2318 (1997).
Yang, et al. , “Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,”Protein Engineering, 16(10): 761-770 (2003).
Uchio, et al., “Site-specific insulin conjugates with enhanced stability and extended action profile,”Advanced Drug Delivery Reviews, 35: 289-306 (1999).
Stimmel, et al., “Site-specific Conjugation on Serine→Cysteine Variant Monoclonal Antibodies,”The Journal of Biological Chemistry, 275 (39): 30445-30450 (2000).
Lee, et al., “Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds,”Bioconjugate Chem., 10: 973-981 (1999).
Cantin, et al., “Polyethylene Glycol Conjugation at Cys232Prolongs the Half-Life of α1 Proteinase Inhibitor,”American Journal of Respiratory Cell Molecular Biology, 27: 659-665 (2002).
Andrew P. Chapman, “PEGylated antibodies and antibody fragments for improved therapy: a review,”Advanced Drug Delivery Reviews, 54: 531-545 (2002).
Yoshioka, et al., “Optimal site-specific PEGylation of mutant RNF-α improves its antitumor potency,”Biochemical and Biophysical Research Communications, 315: 808-814 (2004).
Lee, et al., “N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor,” Pharmaceutical Research, 20 (5): 818-825 (2003).
Clark, et al., “Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol,”The Journal of Biological Chemistry, 271 (36): 21969-21977 (1996).
Haruya Sato, “Enzymatic procedure for site-specific pegylation of proteins,”Advanced Drug Delivery Reviews, 54: 487-504 (2002).
Hinds, et al., “Effects of PEG conjugation on insulin properties,”Advanced Drug Delivery Reviews, 54: 505-530 (2002).
Leong, et al., “Adapting Pharmacokinetic Properties of a Humanized Anti-Interleukin-8 Antibody for Therapeutic Applications Using Site-Specific Pegylation,”Cytokine, 16 (3):106-119 (2001).
Seely, et al., “Issues encountered in the production of site-specific mono-PEGylated therapeutic proteins,”Polymer Preprints(American Chemical Society, Division of Polymer Chemistry), 38(1): 572-573 (1997).
Zalipsky, et al., “Reversible PEGylation: thiolytic regeneration of active protein from its polymer conjugates,”Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, Jun. 9-14, 2001, pp. 953-954.
Benjamin, et al., “The Antigenic Structure of Proteins: A Reappraisal,”Ann. Rev. Immunol., 1984, vol. 2, pp. 67-101.
Francis, et al., “PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques,”International Journal of Hematology, 1998, vol. 68, pp. 1-18.
Katre, et al., “Chemical Modification of Recombinant Interleukin 2 by Polyethylene Glycol Increases its Potency in the Murine Meth A Sarcoma Model,”Proc. Natl. Acad. Sci., 1987, vol. 84, pp. 1487-1491.
Kim, et al., “Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18,”The Journal of Biological Chemistry, 2002, vol. 277, No. 13, pp. 10998-11003.
Kirkpatrick, et al., “A bicistronic Expression System for Bacterial Production of Authentic Human Interleukin-18,”Protein Expression and Purification, 2003, vol. 27, pp. 279-292.
Yi, et al. ,“Asp126, Asp130and Asp134are Necessary for Human IL-18 to Elicit IFN-γ Production from PBMC,”Acta Biochimica et Biophysica Sinica, 2001, vol. 33, No. 4, pp. 368-372.
Bam Narendra
Bongers Jacob
Janson Cheryl A.
Johanson Kyung
Jonak Zdenka
Gimmi Edward R.
Hecht Elizabeth J.
Knowles Sherry M.
Nickol Gary B.
SmithKline Beecham Corporation
LandOfFree
Conjugates comprising human IL-18 and substitution mutants... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates comprising human IL-18 and substitution mutants..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates comprising human IL-18 and substitution mutants... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865251